Balyasny Asset Management
NDRM

Balyasny Asset Management’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Balyasny Asset Management’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-110,800
Closed -$3.31M – 2238
2017
Q2 		$3.31M Buy
110,800
+67,600
+156% +$1.75M 0.01% 843
2017
Q1 		$1.15M Buy
+43,200
New +$1.07M 0.01% 1056

Other funds holding NDRM

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CFIC
City Financial Investment Company London, United Kingdom $562M AUM 5.93% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return

Balyasny Asset Management's NDRM Position: Q3 2017 in Review

Balyasny Asset Management sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 110,800 shares — an estimated $3.31M sold.

Balyasny Asset Management first reported a position in NDRM in Q1 2017 and held it in 2 quarters. The position peaked at $3.31M in Q2 2017. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

  • Balyasny Asset Management reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Balyasny Asset Management sold 110,800 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $3.31M.
  • Balyasny Asset Management first reported a position in NeuroDerm Ltd. Ordinary Shares in Q1 2017 and held it in 2 quarters.
  • Balyasny Asset Management's NeuroDerm Ltd. Ordinary Shares position peaked at $3.31M in Q2 2017.
  • 81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on Balyasny Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.